TrialID,Date_registration_format,Date_enrollment_format,prospective,manual,study_arm,url,Scientific_title,Conditions,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,primary_purpose,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Phase,Public_title,Countries,Primary_sponsor,Interventions
EUCTR2016-004133-25-Outside-EU/EEA,15/12/2016,NA,No,Unreported,im,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004133-25,"A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population Aged 5 Through 17 Years of Age.",Prophylaxis for influenza virus infection <br>MedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],Yes,Yes,Yes,NA,NA,NA,NA,NA,EUCTR,Phase 3,No,Yes,No,No,No,No,Yes,NA,industry,2222,Yes,NA,NA,NCT02545543,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",FALSE,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to evaluate the immunogenicity and safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a pediatric population aged 5 through to 17 years of age,United States,Seqirus GmbH,<br>Trade Name: Afluria Quadrivalent<br>Product Name: Seqirus Quadrivalent Inactivated Influenza Vaccine (Seqirus QIV)<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ VICTORIA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Fluarix Quadrivalent<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>
EUCTR2018-002303-33-ES,21/05/2019,24/04/2019,No,Yes,main,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002303-33,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy",Focal-Onset Seizures <br>MedDRA version: 20.0Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],Yes,Yes,Yes,NA,NA,NA,NA,NA,EUCTR,Phase 3,No,Yes,Yes,Yes,Yes,No,Yes,Treatment,industry,555,NA,NA,NA,NCT03739840,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 4",FALSE,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy,Serbia;United States;Portugal;Estonia;Slovakia;Greece;Spain;Italy;Switzerland;France;Denmark;Netherlands;Bosnia and Herzegovina;Finland;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden,UCB Biopharma SPRL,<br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>
EUCTR2018-002876-41-FR,08/08/2018,NA,No,Yes,im,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002876-41,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration) - PROLISA,"Respiratory Distress Syndrome of preterm babies born < 32 weeks of gestational age;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]",Yes,Yes,Yes,NA,NA,NA,NA,NA,EUCTR,Phase 3,No,No,No,No,Yes,No,NA,NA,NA,542,NA,NA,NA,FALSE,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",FALSE,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration),France,CHU Grenoble-Alpes,<br>                Trade Name: PROPOFOL LIPURO 1%<br>                Product Name: PROPOFOL<br>                Pharmaceutical Form: Emulsion for injection/infusion<br>                Pharmaceutical form of the placebo: Emulsion for injection<br>                Route of administration of the placebo: Intravenous use<br><br>
EUCTR2019-001085-15-BE,22/08/2019,06/11/2019,Yes,No,main,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001085-15,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections. - HEARTH-OF Study.",Patients presenting recurrent orofacial herpes infections (6 or more episodes within the 12-months’ period prior to their study entry). <br>                MedDRA version: 20.0                Level: HLT                Classification code 10019972                Term: Herpes viral infections                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 20.1                Level: PT                Classification code 10067152                Term: Oral herpes                System Organ Class: 10021881 - Infections and infestations             <br>                MedDRA version: 21.1                Level: PT                Classification code 10019948                Term: Herpes simplex                System Organ Class: 10021881 - Infections and infestations            ;Therapeutic area: Diseases [C] - Virus Diseases [C02],Yes,Yes,Yes,NA,NA,NA,NA,NA,EUCTR,Phase 4,No,No,No,No,Yes,No,NA,NA,NA,100,NA,NA,NA,FALSE,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",FALSE,Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.",Belgium,LABO’LIFE Belgium sprl,<br>                Trade Name: 2LHERP®<br>                Product Name: 2LHERP®<br>                Pharmaceutical Form: Pillules<br>                Pharmaceutical form of the placebo: Pillules<br>                Route of administration of the placebo: Oromucosal use<br><br>
EUCTR2019-001155-39-GB,16/07/2019,22/11/2019,Yes,No,main,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001155-39,"A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTIONS",Solid tumors and primary central nervous system (CNS) tumors <br>MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864 <br>MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04],No,Not applicable,No,No,No,No,No,No,EUCTR,Phase 2,No,Yes,No,No,Yes,No,Yes,Treatment,industry,68,NA,NA,NA,EUCTR2019-001155-39-FR,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",FALSE,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,A Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who Have No Satisfactory Treatment Options,United States;France;Spain;Germany;Italy;United Kingdom,F. Hoffmann-La Roche Ltd,"<br>Product Name: Entrectinib<br>Product Code: RO7102122/F03<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F01<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F08<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F09<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F11<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F04<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F06<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concen"
EUCTR2019-004010-34-PL,05/11/2019,18/05/2020,Yes,No,main,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004010-34,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study - ClaTBI/2019","Accute myeloid leukemia <br>MedDRA version: 21.0Level: LLTClassification code 10028557Term: Myeloid leukemia, acuteSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]",No,Not applicable,No,No,No,No,No,No,EUCTR,Phase 2,No,No,No,No,Yes,No,NA,NA,NA,16,NA,NA,NA,FALSE,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",FALSE,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,"Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia - a pilot, single-phase, II phase study",Poland,"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie – Panstwowy Instytut Badawczy, Oddzial w Gliwicach",<br>Product Name: Cladribine<br>Pharmaceutical Form: Infusion<br><br>
EUCTR2020-001635-27-FR,06/04/2020,04/05/2020,Yes,No,covid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27,"A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.","Hospitalized Moderate and Severe COVID-19 Patients <br>MedDRA version: 20.0
Level: SOC
Classification code 10021881
Term: Infections and infestations
System Organ Class: 10021881 - Infections and infestations
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",Yes,Yes,No,No,No,No,No,No,EUCTR,Phase 2,No,No,No,No,Yes,No,NA,Treatment,NA,NA,NA,Yes,NA,FALSE,"Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
",FALSE,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients.,France,AB Science,"<br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Isoquercetin <br>Product Code: IQC950AN <br>Pharmaceutical Form: Capsule, soft<br><br>Trade Name: Plaquenil 200 mg<br>Pharmaceutical Form: Coated tablet<br>CAS Number: 747-36-4<br>Current Sponsor code: SAR321068<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>"
EUCTR2020-002225-29-FR,30/04/2020,12/11/2020,Yes,No,covid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002225-29,Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,"COVID positive patients with respiratory impairment <br>MedDRA version: 23.1
Level: LLT
Classification code 10084437
Term: COVID-19 PCR test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.1
Level: PT
Classification code 10084460
Term: COVID-19 treatment
System Organ Class: 10042613 - Surgical and medical procedures
;Therapeutic area: Diseases [C] - Virus Diseases [C02]",Yes,Yes,Yes,NA,NA,NA,NA,NA,EUCTR,Phase 2,No,No,No,No,Yes,No,NA,NA,NA,45,NA,NA,NA,FALSE,"Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
",FALSE,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections.,France,Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche,"<br>Trade Name: BERINERT<br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: C1-esterase inhibitor, human<br>Other descriptive name: C1 ESTERASE INHIBITOR (HUMAN)<br>Concentration unit: U unit(s)<br>Concentration type: equal<br>Concentration number: 2000-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: FIRAZYR<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ICATIBANT<br>CAS Number: 138614-30-9<br>Other descriptive name: ICATIBANT ACETATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>"
EUCTR2020-002668-29-GB,10/06/2020,25/06/2020,Yes,No,covid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29,"A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)

 - PEX in severe COVID-19","COVID-19;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]",Yes,Yes,No,No,No,No,No,No,EUCTR,Phase 2,No,No,No,No,Yes,No,NA,Treatment,non_industry,40,NA,NA,NA,FALSE,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: standard of care<br>Number of treatment arms in the trial: 2<br>",FALSE,"Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",plasma exchange in severe COVID-19 infection,United Kingdom,University College London,<br>Trade Name: OctaplasLG<br>Product Name: OctaplasLG<br>Pharmaceutical Form: Solution for infusion<br><br>
IRCT2016052828134N1,21/06/2016,30/01/2016,No,Yes,im,http://en.irct.ir/trial/22888,Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,Condition 1: Pneumonia. Condition 2: dental plaque. Condition 3: dental plaque. <br>Influenza and pneumonia <br>Deposits [accretions] on teeth <br>Caries of dentine;Influenza and pneumonia;Deposits [accretions] on teeth;Caries of dentine,Yes,Yes,Yes,NA,NA,NA,NA,NA,IRCT,Phase 2,No,No,No,Yes,No,No,NA,Prevention,non_industry,79,NA,NA,NA,FALSE,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",FALSE,2,Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,Iran (Islamic Republic of),Research Deputy of Shahid Beheshti university of medical sciences,"Intervention 1: intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days. Intervention 2: Control group: Using 15 ml of normal saline, every 12 hours, for 4 days.;Treatment - Drugs;Treatment - Drugs;intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days.;Control group: Using 15 ml of normal saline, every 12 hours, for 4 days."
IRCT20190410043236N1,08/07/2019,02/05/2016,No,Yes,main,http://en.irct.ir/trial/38837,Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,Condition 1: Systolic Heart failure. Condition 2: Systolic Heart failure. <br>IX Diseases of the circulatory system <br>Left ventricular failure;130-152;150.1,Yes,Yes,Yes,NA,NA,NA,NA,NA,IRCT,Phase 3,No,No,No,Yes,No,No,NA,Treatment,non_industry,80,NA,NA,Yes,FALSE,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In present study, simple randomization method was used, Blinding description: This double-blind study was carried out and the cardiologist who do echocardiography patients, as well as those taking medication or placebo, are blind.",FALSE,02-Mar,Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure,Iran (Islamic Republic of),Zanjan University of Medical Sciences,"Intervention 1: Intervention group: Intervention group: A 50000 unit capsule of vitamin D, manufactured by Abidi company, is given weekly and at 50,000 units for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months. Intervention 2: Placebo group: Appearance of 50,000 capsules of vitamin D, manufactured by Abidi company, is given weekly for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months."
IRCT20190525043702N1,05/06/2019,22/05/2019,No,Yes,main,http://en.irct.ir/trial/39866,Effect of antiseptic and antibiotic usage within the implant on the pro-inflammatory cytokines interleukin 1ß and interleukin 6 in gingival crevicular fluid for the contact of the implant and abutment,"Implantytis. <br>Unspecified complication of internal prosthetic device, implant and graft;T85.9",Yes,No,No,No,No,No,No,No,IRCT,Undefined,No,No,No,Yes,No,No,NA,Prevention,non_industry,24,NA,Yes,NA,FALSE,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",FALSE,N/A,Effect of antiseptic and antibiotic usage within the implant in gingival crevicular fluid for the contact of the implant and abutment,Iran (Islamic Republic of),Tabriz University of Medical Sciences,Intervention 1: First Intervention group: The study is split mouth and each patient will have chlorohexidine 2% in first implant. Intervention 2: Second Intervention group: The study is split mouth and each patient will have tetracycline 3% in second implant. Intervention 3: Third Intervention group: The study is split mouth and each patient will have Saliva in third implant. Intervention 4: Control group: The study is split mouth and each patient will have dry environments in control implant.
ISRCTN88057279,14/05/2020,01/10/2020,Yes,No,covid,http://isrctn.com/ISRCTN88057279,PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT),"COVID-19 (SARS-CoV-2 infection) in dialysis, vasculitis, and kidney transplant patients <br>Infections and Infestations",Yes,Yes,No,No,No,No,No,No,ISRCTN,Phase 3,No,No,No,No,Yes,No,Yes,Prevention,non_industry,500,NA,Yes,NA,FALSE,<br>                Open-label multi-centre randomized controlled trial<br>                (Prevention)<br>,FALSE,Phase II/III,Preventative treatment for patients at risk of COVID-19 infection (PROTECT),United Kingdom,Cambridge University Hospitals NHS Foundation Trust,"<br>                Patients will be randomised to receive either 1:1 oral hydroxychloroquine (HCQ) or standard care (no HCQ). Randomisation will be carried out using a validated bespoke automated randomisation system. Randomisation will be stratified by PROTECT sub-group, age and centre.<br><br>                Haemodialysis subgroup<br>                Dosing: 600 mg per week given as 200 mg three times per week after each haemodialysis session for 6 months<br><br>                Vasculitis and transplant subgroups<br>                Dosing: 800 mg for first 2 days followed by 400 mg once a week for 6 months<br><br>                Duration of follow up (all subgroups):<br>                Until the end of the trial, on average 6 months<br>"
JPRN-UMIN000035965,21/02/2019,20/02/2019,No,Yes,main,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040963,NA,Glossodynia,No,Not applicable,NA,NA,NA,NA,NA,NA,JPRN,Unreported,No,No,No,Yes,No,No,NA,NA,non_industry,15,NA,NA,NA,FALSE,Single arm Non-randomized,FALSE,Not selected,The effects of Goreisan on pain perception in Glossodynia associate with dry mouth,Japan,Nagasaki University,Goreisan
NCT03160118,24/03/2017,27/03/2017,Yes,No,im,https://clinicaltrials.gov/show/NCT03160118,A Clinical Study of Biomarkers of Innate and Adaptive Immune Activation Associated With Symptoms and Immune Responses After Administration of a Single Dose of a Quadrivalent Inactivated Split Virus Influenza Vaccine to Healthy Young Adults.,Prevention of Influenza;Prevention of Influenza;Prevention of Influenza;Prevention of Influenza,No,Not applicable,No,No,No,No,No,No,CT.gov,Phase 4,No,No,No,No,Yes,No,NA,Other,non_industry,20,Yes,NA,NA,FALSE,Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).,FALSE,Phase 4,Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults,Belgium;Belgium;Belgium;Belgium;Belgium,"University Hospital, Ghent","Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine"
NCT03208361,26/06/2017,05/11/2013,No,Yes,im,https://clinicaltrials.gov/show/NCT03208361,Efficacy of High Doses of Oral Penicillin V Versus High Doses of Oral Amoxicillin in the Treatment of Non-severe Community-acquired Pneumonia in Adults,Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP),Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,CT.gov,Phase 3,No,No,No,No,Yes,No,NA,Treatment,non_industry,43,NA,NA,NA,EUCTR2012-003511-63-ES,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",FALSE,Phase 3,Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.,Spain;Spain;Spain;Spain;Spain,Jordi Gol i Gurina Foundation,Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin
NCT03856164,21/02/2019,17/06/2019,Yes,No,main,https://clinicaltrials.gov/show/NCT03856164,Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,Post Partum Hemorrhage;Fibrinolysis; Hemorrhage;Blood Loss,Yes,Yes,Yes,Yes,Yes,Yes,No,No,CT.gov,Phase 3,No,Yes,No,No,No,No,NA,Prevention,non_industry,110,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",FALSE,Phase 2/Phase 3,Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery,United States,University of Texas Southwestern Medical Center,Drug: Tranexamic Acid;Drug: Placebo
NCT03926377,15/04/2019,01/04/2019,No,Unreported,main,https://clinicaltrials.gov/show/NCT03926377,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,Osteoporosis;Bullous Pemphigoid,No,Not applicable,No,No,No,No,No,No,CT.gov,Phase 4,NA,NA,NA,NA,NA,NA,NA,Treatment,non_industry,50,NA,NA,NA,FALSE,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,TRUE,Phase 4,Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid,NULL,"Centre Hospitalier Universitaire, Amiens",Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate
NCT04078386,18/07/2019,28/06/2019,No,Yes,main,https://clinicaltrials.gov/show/NCT04078386,"A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome",Primary Sjögren's Syndrome,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,CT.gov,Phase 2,No,No,No,Yes,No,No,NA,Treatment,NA,30,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",FALSE,Phase 2,A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome,China,RemeGen,Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg
NCT04114747,23/09/2019,31/08/2020,Yes,No,main,https://clinicaltrials.gov/show/NCT04114747,"Impact of Continuous Renal Replacement Therapy on Renal Oxygenation, Blood Flow and Function",AKI;Continuous Renal Replacement Therapy;Dialysis;Intensive Care;Renal Blood Flow;Renal Failure;Blood Pressure,Yes,Yes,No,No,No,No,No,No,CT.gov,Undefined,No,No,No,No,Yes,No,NA,Prevention,non_industry,20,NA,NA,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,FALSE,N/A,Renal Physiology During Continuous Renal Replacement Therapy,Sweden,"Sahlgrenska University Hospital, Sweden",Other: Starting at high or low blood pressure
NCT04293887,15/02/2020,01/03/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04293887,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1ß in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",COVID-19;Recombinant Human Interferon a1ß,Yes,Yes,No,No,No,No,No,No,CT.gov,Phase 1,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,NA,Treatment,non_industry,328,NA,Yes,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,Early Phase 1,Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients,NA,Tongji Hospital,Drug: Recombinant human interferon a1ß
NCT04342728,08/04/2020,08/04/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04342728,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",COVID;Corona Virus Infection,Yes,Yes,No,No,No,No,No,No,CT.gov,Undefined,No,Yes,No,No,No,No,NA,Other,non_industry,520,NA,NA,NA,FALSE,Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,FALSE,N/A,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,United States,The Cleveland Clinic,Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care
NCT04345861,05/04/2020,11/04/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04345861,Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,"Coronavirus Infection;Pneumonia, Viral",Yes,Yes,Yes,Yes,No,Yes,No,No,CT.gov,Phase 3,No,No,No,No,Yes,No,NA,Treatment,non_industry,7,NA,Yes,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",FALSE,Phase 2/Phase 3,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),France,"University Hospital, Montpellier",Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin
NCT04350580,08/04/2020,11/04/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04350580,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Acute Respiratory Distress Syndrome;COVID-19,Yes,Yes,Yes,Yes,Yes,No,No,No,CT.gov,Phase 3,No,No,No,No,Yes,No,NA,Treatment,non_industry,138,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",FALSE,Phase 3,Polyvalent Immunoglobulin in COVID-19 Related ARds,France,Centre Hospitalier St Anne,Drug: Human immunoglobulin;Drug: Placebo
NCT04366908,25/04/2020,28/04/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04366908,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS),SARS-CoV 2;COVID19;SARS (Severe Acute Respiratory Syndrome);Cytokine Release Syndrome;Cytokine Storm,Yes,Yes,No,No,No,No,No,No,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,Unreported,NA,Treatment,non_industry,1008,NA,NA,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,Phase 2,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,NA,Maimónides Biomedical Research Institute of Córdoba,Drug: BAT + Calcifediol;Drug: BAT
NCT04460651,02/07/2020,14/08/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04460651,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,COVID19,Yes,Yes,Yes,Yes,Yes,Yes,No,No,CT.gov,Phase 3,No,No,Yes,No,No,No,NA,Treatment,NA,2000,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",FALSE,Phase 3,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Argentina,Estudios Clínicos Latino América,Drug: Icosapent ethyl (IPE);Drug: Placebo
NCT04470531,11/07/2020,12/07/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04470531,Role of Co-trimoxazole in Severe COVID-19 Patients,Covid19;Severe COVID-19 Patients,Yes,Yes,No,No,No,No,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,NA,Treatment,non_industry,94,NA,NA,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,Phase 2,Role of Co-trimoxazole in Severe COVID-19 Patients,Bangladesh,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Drug: oral co-trimoxazole
NCT04494399,28/07/2020,29/07/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04494399,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Covid19,Yes,Yes,No,No,No,No,No,No,CT.gov,Phase 2,No,No,No,Yes,No,No,NA,Treatment,non_industry,96,NA,Yes,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,Phase 2,IFN Beta-1b and Ribavirin for Covid-19,Hong Kong,The University of Hong Kong,Drug: Interferon beta-1b;Drug: Ribavirin
NCT04498936,14/04/2020,15/07/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04498936,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",COVID,Yes,Yes,No,No,No,No,No,No,CT.gov,Phase 4,Yes,No,No,No,No,No,NA,Treatment,non_industry,240,NA,Yes,NA,FALSE,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,Phase 4,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Egypt,Assiut University,Drug: Sofosbuvir and Ledipasvir;Drug: Nitazoxanide
NCT04563702,21/09/2020,21/09/2020,Yes,No,covid,https://clinicaltrials.gov/show/NCT04563702,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers",Covid19,NA,No,No,No,No,No,No,No,CT.gov,Phase 1,No,Yes,No,No,No,No,NA,Prevention,NA,35,NA,NA,NA,FALSE,Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).,FALSE,Phase 1,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,United States,Vaxart,Biological: VXA-CoV2-1